Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 6/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761154 | 0.89 | CYP2C9 (0.64) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1108960 | 0.84 | CYP2C9 (0.52) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3063016 | 0.81 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10969202 | 0.80 | FABP6 (0.47) | FABP6MASP2MEN1ALDH1A1NUDT1 | |
| SCHEMBL6027004 | 0.77 | ALDH1A1 (0.46) | CYP2C9CYP2C19FABP6MASP2MEN1 | |
| SCHEMBL28209330 | 0.77 | IRAK4 (0.53) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12684800 | 0.75 | LMNA (0.56) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3500724 | 0.72 | ATP4A (0.46) | CYP1A2CYP2D6FABP6MASP2MEN1 | |
| SCHEMBL4704694 | 0.71 | TAS2R14 (0.57) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5679917 | 0.71 | FABP6 (0.47) | FABP6MASP2MEN1ALDH1A1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118880330-A | Copper etching solution for copper wiring process of packaging circuit substrate and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-115128195-B | LC-MS/MS detection method for pesticide and veterinary drug residues in animal oil and vegetable oil | 北京市疾病预防控制中心 | 2022-11-15 | — | — | CN | claimed |
| CN-115128195-A | LC-MS/MS detection method for pesticide and veterinary drug residues in animal oil and vegetable oil | 北京市疾病预防控制中心 | 2022-09-30 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-06-03 | — | — | US | claimed |
| CN-118880330-A | Copper etching solution for copper wiring process of packaging circuit substrate and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1773828-A1 | HETEROCYCLE -SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-04-18 | — | — | EP | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
| WO-2006010642-A1 | HETEROCYCLE-SUBSTITUTED CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-02-02 | — | — | WO | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | CYP2C9 1736/4885CYP2C19 2857/4885CYP1A2 2569/4885 |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | CYP2C9 708/4885CYP2C19 442/4885CYP1A2 803/4885 |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | CYP2C9 4157/4885CYP2C19 4283/4885CYP1A2 4489/4885 |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | CHP1, CMA1, CARHSP1 | CYP2C9 2541/4885CYP2C19 3340/4885CYP1A2 2066/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | CYP2C9 3177/4885CYP2C19 3945/4885CYP1A2 3922/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | CYP2C9 4157/4885CYP2C19 4283/4885CYP1A2 4489/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | CYP2C9 3236/4885CYP2C19 4001/4885CYP1A2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.